Howard Hughes Medical Institute/Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, United States.
Vaccine. 2012 Aug 3;30(36):5302-4. doi: 10.1016/j.vaccine.2012.04.088. Epub 2012 May 31.
Early clinical investigations of candidate malaria vaccines and antimalarial medications increasingly employ an established model of controlled human malaria infection (CHMI). Study results are used to guide further clinical development of vaccines and antimalarial medications as CHMI results to date are generally predictive of efficacy in malaria-endemic areas. The urgency to rapidly develop an efficacious malaria vaccine has increased demand for efficacy studies that include CHMI and the need for comparability of study results among the different centres conducting CHMI. An initial meeting with the goal to optimize and standardise CHMI procedures was held in 2009 with follow-up meetings in March and June 2010 to harmonise methods used at different centres. The end result is a standardised document for the design and conduct of CHMI and a second document for the microscopy methods used to determine the patency endpoint. These documents will facilitate high accuracy and comparability of CHMI studies and will be revised commensurate with advances in the field.
早期候选疟疾疫苗和抗疟药物的临床研究越来越多地采用已建立的疟疾感染控制模型(CHMI)。研究结果用于指导疫苗和抗疟药物的进一步临床开发,因为迄今为止的 CHMI 结果通常可以预测在疟疾流行地区的疗效。快速开发有效疟疾疫苗的紧迫性增加了对包括 CHMI 的疗效研究的需求,以及对不同进行 CHMI 的中心的研究结果进行可比性的需求。2009 年举行了一次会议,目的是优化和标准化 CHMI 程序,2010 年 3 月和 6 月举行了后续会议,以协调不同中心使用的方法。最终结果是一份 CHMI 设计和实施的标准化文件,以及一份用于确定通透性终点的显微镜方法的第二份文件。这些文件将促进 CHMI 研究的高度准确性和可比性,并将根据该领域的进展进行修订。